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Side effects from antiretroviral drugs (ARVs) over time, present a major 
challenge to individuals on treatment and is a major cause of dropouts from 
treatment programs. The provision of treatment for the infected varies de-
pending on their levels of affordability in many developing countries. In 
this thesis, we formulate a mathematical model to determine the impact of 
dropouts on the dynamics of HIV/AIDS which depends on different health 
care systems. We categorize the health care systems into two, private and 
public with the dropout rates being dependent on the health care system. 
The model’s steady states are determined and their stabilities presented in 
terms of the reproduction number, R0. Numerical simulations are carried 
out and the results suggest that the management of dropouts is significant to 
the dynamics and management of HIV/AIDS. The role of essential parame-
ters is also investigated through sensitivity analysis that employs the Latin 
Hypercube Sampling technique. The results have implications to the man-
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Newe-effekte van antiretrovirale medisyne (ARV’s) met verloop van tyd, is 
’n groot uitdaging vir individue wat op behandeling is en is die grootste oor-
saak van die uitval van behandelingsprogramme. Die verskaffing van be-
handeling vir besmette wissel afhangend van hul bekostigbaarheidsvlakke 
in baie ontwikkelende lande. In hierdie tesis formuleer ons ’n wiskundige 
model om die impak van uitvalle op die dinamika van MIV / VIGS te be-
paal wat afhang van verskillende gesondheidsorgstelsels. Ons kategoriseer 
die gesondheidsorgstelsels in twee, privaat en publiek, en die uitvalkoers 
is afhanklik van die gesondheidsorgstelsel. Die standvastoestande van die 
model word bepaal en hul stabiliteit word aangebied in terme van die repro-
duksienommer, R0. Numeriese simulasies word uitgevoer en die resultate 
dui daarop dat die bestuur van uitvalle belangrik is vir die dinamika en 
hantering van MIV / VIGS. Die rol van essensiÃ«le parameters word ook 
ondersoek deur middel van sensitiwiteitsanalise wat gebruik maak van die 




die bestuur en beleidsontwerpe ten opsigte van gesondheidsorgstelsels, uit-
valle en progressie van siektes.
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1.1 HIV/AIDS: General overview
The Human Immunodeficiency Virus (HIV) is a virus that causes an infec-
tion that can progress to Acquire Immunodeficiency Syndrome (AIDS) if
the infected are not treated [89]. HIV is different from some other viruses
because once an individual is infected with the virus, they have it for a life-
time. This is because there is currently no cure for HIV, but with adequate
medical attention and care, it can be managed. HIV is a virus that spread
through body fluids and attacks the body’s immune system. Specifically,
HIV attacks the CD4+ T cells (types of white blood cells that move through-
out the body to fight and destroy viruses, germs, bacteria, etc), macrophages
and dendritic cells. It destroys many of these cells and the cells will be un-
able to fight against any disease or infections [26]. A normal CD4+ T cell
count is between 500− 1400 cells per cubic millimetre of blood in humans.
HIV infection leads to a reduction in the count of CD4+ T cell. And when
the CD4+ T cells decrease to a particular level (< 200 cells per cubic mil-
limetre of blood), the immune system will no longer function properly and
this causes the body to be susceptible to other infections and diseases, which
eventually leads to the development of AIDS.
HIV is a member of the genus Lentivirus, which is part of the family of
retroviruses [63]. Lentiviruses have properties that are common biologi-
cally. They are responsible for illnesses that have a long duration and with
a long incubation period. HIV structure is roughly spherical and the diame-
1
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ter is about 120nm which is about 60 times smaller than a red blood cell [63].
There are two main types of HIV: HIV-1 and HIV-2 [22]. HIV-1 is the virus
that was first discovered and widely known worldwide as the cause of HIV
infections globally. It is called Lymphadenopathy Associated Virus (LAV)
and Human T-lymphotropic Virus 3 (HTLV-III). HIV-1 has a greater chance
of damaging the host and it is more infectious than HIV-2. Generally, HIV-1
is believed to have originated from Southern Cameroon [2]. On the other
hand, HIV-2 is common in West Africa [29]. The viral load of HIV-2 is lower
to that of HIV-1 which results in a lower rate of transmission of the virus[69].
Generally, the belief is that HIV originated from animals in Africa. Scientific
studies concluded that this happened as a result of the transfer of a virus
named Simian Immunodeficiency Virus (SIV) from Chimpanzees or apes to
human beings [2]. Studies also show that the version of the Immunodefi-
ciency Virus (SIV) might have been transmitted to humans from contacts
with monkey blood while hunting for meat to eat [39], and metamorphosed
to HIV in humans.
HIV is transmitted or spread by body fluids of infected individuals such as
semen, vagina fluids, blood, rectal fluids, breast milk and from an infected
mother to the fetus while pregnant, a process commonly known as vertical
transmission. There are three main sources of contracting HIV. A person
can contract HIV by
(i) Having unprotected sex with an HIV infected individual (either by
anal or sometimes oral sex).
(ii) Sharing needles that are already contaminated.
(iii) Through vertical transmission.
1.2 HIV/AIDS control strategies
Controlling HIV/AIDS is a major challenge that the world is facing at the
present moment. The challenges include a lack of medical equipment, illit-
eracy, poverty, poor health care systems, etc. A significant number of people
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have HIV infection but do not know their status. On the other hand, some
know their status but find it difficult to seek treatment and access other
available disease management services [46]. The mode of controlling the
disease presently is by; total abstinence, the use of condoms, screening of
blood before transfusion and treatment of people that are already infected
[65]. Since there is no cure for HIV presently, it is important to make sure
that infected individuals are pre-informed about the available control mea-
sures or precautions so as not to spread the disease. Similarly, individuals
at risk should be educated on HIV infection, so that they avoid getting in-
fected. Currently, with adequate control measures and interventions, HIV
can be managed over a long period.
1.2.1 Treatment for HIV/AIDS
Even though presently there is no cure or vaccine for HIV/AIDS, there is
treatment that can help to reduce the viral load. Antiretroviral (ARV) drugs
are drugs available to people that are infected with HIV and for those that
have not been infected. Pre-exposure Prophylaxis (PrEP) is an ARV drug
that has been found to be useful in preventing infections for people that
have a high chance of being infected with HIV and are usually prescribed.
PrEP, should be taken daily for it to be effective in preventing HIV from
sex or injection drug use. Post-exposure Prophylaxis (PrEP) is an ARV
drug that is approved for individuals that are potentially exposed to HIV,
to prevent becoming infected. PrEP must start within 72hours after a pos-
sible exposure to the virus. The very first ARV drug to be permitted for
use against HIV is called zidovudine, which was available for use in the
year 1987 [87]. This also helped to reduce the risk of transmitting HIV. Re-
cently, Highly Active Antiretroviral Therapy (HAART) was introduced in
1996 [67]. HAART consists of three drugs belonging to at least two types
of antiretroviral agents that help to reduce the viral particles in the body,
increase the number of immune cells (CD4+ T cells), slows down progres-
sion to AIDS, reduce the rate of transmission and prevents the virus from
multiplying in the blood. For ARV drugs to be effective, they must be taken
at the right time and as prescribed. The only way to prevent people from
being infected with HIV is to make sure they are not exposed to the virus.
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1.2.2 UNAIDS 90-90-90 treatment target
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) came
up with an ambitious target to end the AIDS epidemic. According to UN-
AIDS, it will be very difficult to bring the epidemic to an end if HIV treat-
ment is not provided to everybody who is infected with the virus. UNAIDS
has an ambitious 90− 90− 90 target. The target is as follows:
• 90% of all individuals that are living with HIV will know their status
by 2020.
• 90% of all individuals that have been diagnosed with HIV infection
will receive sustained ARV drugs by 2020.
• 90% of all individuals receiving ARV drugs will have viral suppres-
sion.
The above target will have a result such that 81% of all individuals living
with HIV infection will be on treatment and 73% of all individuals living
with HIV achieve viral suppression. This will, in turn, enable the world to
end the AIDS epidemic by 2030 [30]. Although the target is ambitious, sci-
entists believe that it is achievable [77]. The target is a commitment to make
available and improve access to ARVs to HIV infected individuals as a life-
saving treatment and to prevent transmission to uninfected individuals [48].
For the target to be achieved, adequate and efficient delivery of medical care
for HIV infected is needed. These include;
• Series of diagnostic tests: This can be achieved by making sure that
there are awareness and adequate information for people to know
their status.
• Treatment delivery: This also can be achieved by making available
ARV drugs to infected individuals as soon as their status is known.
• Monitoring, giving support and care to infected individuals.
• Adequate Assessments on how the UNAIDS 90− 90− 90 ambitious
targets are being carried out.
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Even though HIV treatment is advocated for the ending of the AIDS epi-
demic, it is not the only method that can help to end the epidemic. Taking
precautionary measures to minimize the spread of the disease is also impor-
tant. When individuals are aware of their status, they are enlightened about
prevention strategies and those that are HIV negative are equally protected.
The prevention strategies that are common for a disease such as HIV/AIDS
are detailed below:
• Condoms: They play an important role in fighting or reducing the
spread of HIV/AIDS because of their ability to prevent sexually trans-
mitted HIV. Therefore, UNIADS target is currently on condom pro-
gramming (male and female condom) to ensure that individuals that
are at risk of contracting HIV are encouraged to use condoms. Con-
doms access and their consistent use are pivotal. The supply of and
demand for condoms is also addressed, making sure condoms are
available and accessible at no cost.
• PrEP: Sexually exposed individuals are encouraged to use PrEP ARV
drugs to reduce the risk of being infected with HIV.
• Male circumcision: Research has shown that male circumcision done
by well-trained health experts in properly equipped settings is very
safe [90]. It has also shown that circumcising male reduces the risk of
HIV infection in men by approximately 60%. Since male circumcision
reduces the rate of HIV infection among men, this indirectly reduces
the risk of exposure of the infection to women [27]. Furthermore, re-
search has shown that male circumcision provides a degree of protec-
tion which is equivalent to what a highly effective vaccine would have
achieved [9]. Therefore, UNAIDS recommended that male circumci-
sion should be considered as an intervention for preventing HIV in
countries that have heterosexual HIV transmission, high HIV preva-
lence, and low male circumcision.
• Elimination of mother-to-child transmission (MTCT): The aims of MTCT
include: making sure that all expectant mothers know their status, up
to 90% of infected mothers to receive ARV drug, up to 90% of infants
that are breastfeeding receive ARV drug and adequate provision of
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care, treatment and support measures for women and children that
are living with HIV and also for their family members [2].
• Reduction in the harm caused by health professionals who inject drugs
and transfuse blood include the screening of blood before transfusion
and adequate sterilization of equipment before use.
Finally, UNAIDS aims to be consistent with the target, and also plan to make
a routine report to track the progress towards the 90-90-90 target [30]. Sen-
sitizing people via media and other awareness channels is also put in place
to eliminate stigma, social exclusion, and discrimination towards HIV pos-
itive individuals. Countries around the world and scientists are working
relentlessly towards achieving this ambitious target of UNAIDS and quite
interesting results are being achieved [10, 36, 47, 48, 51, 56, 77].
1.3 Health care systems
Health care systems can be defined as organizations of people, institutions,
and resources that make available health care services to meet the health
needs of target populations. Health care systems can be categorized into
two, the private and public health care system in many of the developing
countries. Private health care is provided by institutions other than the gov-
ernment to meet the health needs of the people that prefer private health
care and can afford it, while the public health care system is provided or
funded by the government [11]. Public health care, apart from the fact that
the services rendered to people are free or almost free in most countries, it
has a lot of disadvantages. People who go for public health care experience
long waiting periods before they are attended to, the facilities are some-
times old and poorly managed, the quality of care is poor and there is poor
disease control and prevention [94]. This is not so with private health care,
where there are short wait times, appointments are not rushed, better facil-
ities, good care, and better disease control and prevention [94]. Therefore,
the majority of people who can afford prefer to turn to private health care
because of its accessibility, availability, and convenience of services [43, 50].
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1.4 Attrition from HIV treatment
Advancement in the treatment of HIV over time has enabled many indi-
viduals that are infected to enjoy good health, live longer and also have
hope for the future. Despite the improvement in the treatment of HIV, sev-
eral infected individuals that are enrolled in treatment still dropout from
treatment one way or the other [76]. This could be either because infected
individuals do not use the ARV drugs as prescribed or refuse to go for out-
patient health care services due to hostility and public humiliation by health
care staff. Dropouts could also be a result of the side effects they experience
from the ARV drugs. If HIV infected individuals skip doses of ARV drugs,
the virus will, in turn, start replicating once again in their bodies. This can
also make the virus to be resistant to the available drugs. Due to the high
burden of HIV that the world is facing, it implies that the number of peo-
ple on ARV drugs has increased resulting in health systems having a lot of
patients to deal with. Due to the larger population of infected individuals,
the waiting period for patients to receive services is usually longer and the
quality of services is generally poor. This often results in patients being dis-
couraged and often leads to attrition from ARV treatment [44]. Most of the
cases of attrition are as a result of loss to follow up of HIV infected indi-
viduals [8]. Not having a personal desire and self-desire to continue can
also contribute to attrition from ARV treatment [73]. This will affect the pa-
tients because the risk of drug-resistance to HIV will increase enormously
and viral-load in patients will increase [49]. Care is very essential regard-
ing individuals living with HIV/AIDS, but when the care is limited, it can
contribute to individuals dropping out of treatment for those under treat-
ment. Generally, private health care has fewer dropouts when compared
with public health care systems.
1.4.1 Side effects of antiretroviral drugs
The side effects of ARV drugs are an important consideration in manag-
ing individuals that are infected with HIV. HIV infection is a disease that is
chronic and as a result, many drugs are used by HIV infected persons for
a long period [16]. Therefore, if there is no proper adherence to the way
the drugs are administered, it could then lead to side effects as a result of
the use of the medication [7]. Physicians noted that the reason that is com-
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mon for HIV infected patients to refuse to continue treatment is due to fear
of side effects, the actual side effects, and complications of the treatment
[12]. The fact remains that it is still very difficult for HIV infected individ-
uals to adhere to the treatment plan because they have to take these drugs
for the rest of their lives. Side effects from ARV drugs could be so serious
at times that they make infected individuals stop treatment. HIV infected
individuals also have a higher chance of having secondary infections and
the medications for those infections could cause side effects when they are
taken concurrently with ARV drugs. Listed below are some of the severe
and life-threatening side effects caused by ARV drugs [1, 34, 75].
• They cause hypersensitivity or allergic reactions (such as rash, swellings
in the eyes, tongue, lips, hands, etc).
• They cause heart disease.
• They lead to kidney, liver or pancreas damage.
• High blood sugar and diabetes.
• Pain in the feet or hands as a result of nerve problems.
• They might also make some people have trouble sleeping.
• Feeling nausea and vomiting.
• They cause depression, anxiety and leads to changes in mood.
• They cause lipodystrophy (gaining or losing fat in certain areas of the
body).
• They cause diarrhoea.
• They lead to loss of appetite.
• They also cause fatigue.
Therefore side effects to ARV drugs are a serious challenge the world is
facing regarding the HIV/AIDS epidemic.
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1.5 Mathematical modelling of HIV/AIDS
Mathematical models have been used as a tool to study the dynamics of
HIV/AIDS. Mathematical models have enabled us to have a better under-
standing of the long and short term dynamics of the disease [18]. There are
two types of models that are used for modelling HIV/AIDS. These are:
• Stochastic models: These are models based on individual simulations.
In these models, each individual in a population is considered as a dis-
crete entity and the simulations are carried out by random processes
[37]. In stochastic models, a probabilistic approach is used to predict
future events.
• Deterministic models: These are models that are based on popula-
tion averages. In these models, it is assumed that all the individuals in
the population have the same characteristics. Also, unique solutions
are generated when solving models. Furthermore, the outcomes are
determined precisely through known relationships among events and
states. These models do not consider random variations [17]. Popu-
lations in these models are divided into different compartments de-
pending on their infection status [40]. Differential equations are used
to describe the changes in each compartment, which helps to deter-
mine the dynamics of each of the compartments. Deterministic mod-
els also enable us to determine variables and parameters that can be
used in case of the inclusion of control variables when modelling dis-
ease control.
The use of either stochastic models or deterministic models is determined
by the epidemiology of the infection, the population size and the assump-
tions built in the models.
1.6 Motivation
HIV/AIDS remains a global problem. Researchers are working tirelessly on
how to put an end to the AIDS epidemic [82]. To date, there is no vaccine
or cure for this disease except for ARV drugs that are used to suppress the
viral load. Likewise, issues of dropouts from HIV treatment are also a great
challenge. Therefore, it is important to determine the impact of dropouts on
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the dynamics of the disease.
A number of HIV/AIDS models have been developed, analyzed and sim-
ulated but many of them do not include or consider side effects of ARV
drugs, which is the driving force for why people dropout from treatment.
Although, [78] considered dropout as a result of the loss of follow up from
the health care setting, the differences in health care services were not con-
sidered. Poor health care services are a propelling factor that leads people to
drop out of treatment. Some people might decide to make use of the private
health care system and some, public health care system due to the different
levels of affordability. This is crucial to consider when developing a mathe-
matical model for HIV/AIDS.
Since dropping out from HIV treatment has a great impact on the dynamics
of HIV/AIDS, the questions are;
(i) What will be the long-term dynamics of the disease if people keep
dropping out of treatment?
(ii) How will the side effects of ARV drugs drive individuals to drop out
of HIV treatment?
(iii) What is the potential impact of having two types of health care sys-
tems to the HIV/AIDS epidemic?
In [19] a model for HIV/AIDS of the SIT type (Susceptible-Infected-Treated)
models dropouts by including a parameter from the treatment compartment
back to the infected compartment. In this project, the model is extended by
including a class of those that drop out of treatment and different health care
systems. Models of HIV/AIDS that do not consider the effects of dropout
from ARV drugs may not include the full dynamics of HIV/AIDS in the
population, considering the current challenges around treatment and side
effects.
1.7 Objectives
The main objective of this thesis is to study the potential impact of different
health care systems and dropouts on the dynamics of HIV/AIDS, in which
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side effects to ARV drugs are a propelling force that causes the dropouts.
The specific objectives are listed below:
• To develop a deterministic mathematical model that describes the dy-
namics of HIV/AIDS within a population.
• To analyze the model by carrying out a stability analysis of steady
states.
• To determine the reproduction number which enables us to determine
the threshold conditions for disease persistence.
• To carry out the numerical simulations of the model system and also
the sensitivity analysis of the formulated model.
• To fit the model to data from Warren Park, Zimbabwe drawn out from
[19].
• To discuss the effects of dropouts on the dynamics of HIV/AIDS from
the analysis done and make general conclusions.
1.8 Composition of the thesis
This project is structured as follows: Chapter 1 contains the general overview
of HIV/AIDS, control strategies, attrition from HIV treatment and mathe-
matical modelling of HIV/AIDS. The chapter also contains the thesis mo-
tivation, objectives, and overview of the thesis. Chapter 2 consists of the
literature reviews of mathematical models of HIV/AIDS. In Chapter 3, the
model to study the potential impact of different health care systems and
dropouts on the dynamics of HIV/AIDS is formulated. Analysis of the
model (steady states, stability, and reproduction number) is also done in the
chapter. Numerical simulations were performed. The fourth chapter con-
tains the discussion and conclusions. Some suggestions on how to improve




Mathematical modelling of epidemics is used to describe or demonstrate
the dynamics of infectious diseases in a population. Daniel Bernoulli in
the year 1766 was the first to carry out the mathematical modelling of the
spread of diseases that are infectious [35]. The author used the model to
make future predictions with regards to the infectious disease. The origins
of modern-day mathematical modelling of diseases started with Kermack
and McKendrick [40]. They constructed a simple deterministic (compart-
mental) model. The model was a success because it helped in predicting the
behaviour of outbreaks which is similar to what is observed in many epi-
demics that have been recorded [15].
Several mathematical models have been used to study HIV/AIDS epidemics.
These models have enabled us to have a better understanding of HIV/AIDS
dynamics. These include knowing the short and long term impact of the
disease in any given population [18]. These models enable us to know how
changes in behaviour and preventive measures can affect transmission dy-
namics. The models also enable us to know how the disease is impacted by
different population structures.
Dominik and Martin [92] described how mathematical models can be used
to generate new hypotheses regarding the mechanism of disease progres-
sion and the principles underlying immunological control of HIV. One such
control is immunotherapy, which helps to improve the immune responses
against HIV and also helps in the control of the virus. These insights were
applied to guide therapy regimes aimed at the long term control of HIV.
12
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2.1 Earlier models for HIV/AIDS
The early models for HIV/AIDS do not incorporate the policy of treatment
as prevention (TasP). The simplest HIV model has two compartments; sus-
ceptibles S(t), i.e. individuals at risk of getting the infection, and infected
individuals I(t), popularly known as the SI epidemic model with disease-
induced mortality. In the SI models, the assumption is that, once individu-
als are infected with HIV, they experience an increase in the mortality rate.
This is probably the most basic model that can be constructed for HIV trans-
mission and survival [38, 52]. The SI models are based on population av-
erages with no random variations. Differential equations are used and ana-
lytical solutions obtained and with no curve fitting of the model to data.
The SI models were further improved because a simple SI model has an ex-
ponentially distributed time spent in the infectious stage, that is, the prob-
ability of surviving in the stage declines exponentially. This is not very re-
alistic for HIV, where the duration of infectivity is long and the duration is
subject to significant variation [52].
Maia [52] proposed a model to fit the world HIV/AIDS prevalence data.
The SI model was improved by dividing the infected class, I(t), into four
subclasses: I1(t), I2(t), I3(t), and I4(t) in which individuals in all the four
subclasses can infect the susceptible individuals. The disease-induced mor-
tality is from the I4 class only. The model was fitted to the HIV/AIDS preva-
lence data and the results show that the time spent in each of the infectious
classes is approximately 3 years. The flowchart for the model is shown in
Figure 2.1.
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Figure 2.1: Flowchart of the HIV model. Source: [52].
Anulekha and Koushik [80] formulated a mathematical model that describes
the spread of HIV. The model is divided into five classes: Susceptibles S(t),
infected I(t), population initially not infected by HIV but going for unsafe
sex P1(t), HIV infected population going for unsafe sex P2(t), population
initially not infected but getting infected with HIV due to transfusion of
contaminated blood, blood products or by sharing of contaminated needles
P3(t). This model enables a better understanding of how HIV can escalate
or increase in a population.
2.2 HIV/AIDS models driven by policy (test and
treat)
Treatment as Prevention (TasP) can be described as HIV prevention pro-
grams, such as the use of ARV drugs to decrease the risk of HIV transmis-
sion. The Test and Treat strategy is a strategy in which the population that
is at risk are screened for HIV infection and individuals that are diagnosed
with HIV infection receive treatment immediately. According to Williams
et al. [91], TasP has an important role to play in reducing HIV transmission
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which will eventually help in bringing the HIV/AIDS epidemic to an end.
Although, they also concluded that a lot of things still need to be learned,
some obstacles to overcome still remain.
Several mathematical models have been used to study the dynamics of the
HIV/AIDS epidemic with treatments. These models have enabled us to
have a better understanding of the effects of treatment on infected individ-
uals. We describe a few of the models relevant to this study below.
The first test and treat model was proposed by Granich et al. [31] in which
they investigated the conditions under which the HIV epidemic could be
driven towards elimination by universal voluntary HIV testing and imme-
diate treatment with antiretroviral drugs. They used a stochastic model to
determine the effect test and treat strategy on the reproductive number.
They also used a deterministic model to determine the long-term dynam-
ics of the HIV/AIDS epidemic, using South Africa as their case study for
the generalized epidemic. They assumed that all HIV transmission was het-
erosexual. The population that was used was aged 15 years and older. As
soon as they are diagnosed with HIV, individuals start antiretroviral treat-
ment immediately. They concluded that universal voluntary HIV testing
and immediate antiretroviral treatment, combined with present prevention
approaches, could have a major effect on the severity of the HIV/AIDS epi-
demic. They also concluded that this approach merits further mathematical
modelling, research, and broad consultation.
Nyabadza [61], proposed a model for the transmission of HIV with the in-
clusion of prevention strategies, such as the use of a condom, ARV drug
treatment, and voluntary counselling and testing. The model was used to
predict the potential impact of the strategies that are currently being used
to control HIV/AIDS. The model was divided into four compartments: sus-
ceptible S(t), infected I(t), individuals under treatment T(t) and those with
AIDS A(t). The study shows that multiple strategies can be useful in the
control of the spread of the HIV epidemic. The model also shows that a
reduction in the number of sexual contacts and the use of condoms has a
significant impact in reducing the transmission of the disease.
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Bhunu et al. [13] developed a two strain HIV/AIDS model with treatment
which allows AIDS patients with sensitive HIV-strain to improve after treat-
ment. This was presented as a system of non-linear ordinary differential
equations. The model they developed classified the population that is sex-
ually active into five classes, which are: susceptible (S), antiretroviral sen-
sitive HIV infected (I1), AIDS individuals with antiretroviral sensitive HIV
(A1), antiretroviral resistant HIV infected (I2) and AIDS individuals with
antiretroviral resistant HIV (A2). The numerical solutions of the model
show that the two strains co-exist when the reproduction number is more
than 1. Furthermore, treatment may increase the total number of infective
individuals but results in a decrease in the number of AIDS patients. Finally,
the reproduction number analysis showed that as the use of antiretroviral
increases, antiretroviral resistance will also increase.
Rahman et al. [70] developed an in-host model (CD4+ T cell count based)
mathematical model to study the impact of early treatment programs on
HIV epidemic and the overall community-level immunity. The model is di-
vided into seven classes: Susceptible S(t); infected individuals with CD4+
T cell count > 500 cells/mm3, I1(t); infected individuals with CD4+ T cell
count between 350− 500 cells/mm3, I2(t); infected individuals with CD4+
T cell count < 350 cells/mm3, I3(t); treated individuals with CD4+ T cell
count > 500 cells/mm3, T1(t); treated individuals with CD4+ T cell count
between 350− 500 cells/mm3, T2(t), treated individuals with CD4+ T cell
count < 350 cells/mm3, T3(t).This model predicts that the early treatment
of HIV reduces the new infections significantly and increases the community-
level immunity. Although the treatment alone may not be enough to elim-
inate HIV epidemics, these findings, including community-level immunity,
might provide helpful information for the proper implementation of HIV
treatment programs.
Montaner et al. [54] also studied HIV treatment as prevention. They fit-
ted two Poisson regression models over the study period in order to relate
estimated HIV incidence and the number of individuals on HAART and
the percentage of infected individuals that had viral suppression. They
used population-level longitudinal data from province-wide (in Canada)
registries including plasma viral load, CD4 count, drug resistance, HAART
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use, HIV diagnoses, AIDS incidence, and HIV-related mortality. Their mod-
els suggested that for each increase of 100 individuals on HAART, the esti-
mated HIV incidence decreased by 1.2% and also for every 1% increase in
the number of individuals suppressed on HAART, the estimated HIV inci-
dence also decreased by 1%. Their results also show that HAART expansion
was associated with a decrease in morbidity, mortality and HIV transmis-
sion. Their findings suggest and agree with long-term effectiveness and sus-
tainability of HIV treatment as prevention within an adequately resourced
environment with no financial barriers to diagnosis, medical care or ARV
drugs.
Nah et al. [57] proposed a simple mathematical model to understand how
testing and treating have an influence on the population dynamics of HIV/AIDS.
They divided the population into five compartments: susceptible, undiag-
nosed infected individuals without AIDS Hu, diagnosed infected individu-
als Hd, undiagnosed AIDS individuals Au and diagnosed AIDS individuals
Ad. They assumed that all diagnosed individuals are all under antiretroviral
treatment. According to their findings, a decrease in HIV prevalence is asso-
ciated with certain diagnosis coverage, care, and continued treatment. Their
results also suggest for further research because sometimes HIV prevalence
is not necessarily decreased because the test and treat strategy requires long-
term, costly use of antiretroviral therapy.
Rufu et al. [74] studied the implementation of the test and treat policy for
newly diagnosed people living with HIV in Zimbabwe in 2017. They used
data gotten from sixteen mission hospitals in Zimbabwe that were imple-
menting the test and treat program for people living with HIV. They ana-
lyzed the data using multivariate analysis. According to their study, it was
the first from Zimbabwe to report on preliminary results of the test and treat
approach at sixteen mission hospitals in four provinces of the country. Their
findings were encouraging. Firstly, the 94% of people newly diagnosed with
HIV were enrolled in care, and nearly 80% were initiated on antiretroviral
treatment. They were unable to obtain reasons as to why some people did
not enrol in HIV care. They concluded that the test and treat strategy was
successful and feasible, not only in getting newly HIV-infected individuals
initiated on antiretroviral treatment but also initiating the treatment on the
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same day as being HIV tested. They also concluded that further research
needs to be done to better understand the processes involved, benefits of
the test and treat strategy and the potential risks involved in starting treat-
ment and not adhering or attrition.
Narasimhamurthy and Leelavathy [58] proposed a non-linear mathematical
model to study the transmission of HIV/AIDS in a population of varying
size with treatment and vertical transmission under the assumption that
due to sexual interaction of susceptibles and infectives, the infected babies
are born and increase the growth of the infected population directly. The
model is divided into five classes: susceptible S(t), infected I(t), pre-AIDS
patients p(t), treated class T(t) and AIDS patients A(t). They assumed that
patients in pre-AIDS and AIDS classes are not able to produce children. Ac-
cording to their results, an increase in the rate of vertical transmission leads
to an increase in the population of infectives which in turn increases the pre-
AIDS and AIDS population.
Waziri et al. [88], also proposed a nonlinear deterministic model to study
the dynamics of HIV/AIDS with treatment and vertical transmission. They
divided the population into five compartments: susceptible S(t), infectives
I(t), pre-AIDS patients P(t) (this depends on their viral count), treated class
T(t) and AIDS patients A(t). They assumed that the susceptibles become
HIV infected as a result of sexual contact with the infectives which may also
lead to the birth of infected children. A fraction of the newborn children
contract HIV during birth and hence are recruited directly into the infectives
class. Their results suggest that when the rate of vertical transmission is
controlled, there will be a significant reduction in the spread of the disease.
2.3 HIV/AIDS models with dropouts
Despite the fact that a significant amount of research on the importance of
enrolling in treatment for HIV infected individuals and also retaining in
treatment has been done, infected individuals still drop out of treatment for
one reason or the other and have negative effects on the disease dynam-
ics. According to [31, 57, 91] the test and treat strategy only can not make
the AIDS epidemic come to an end. The success of TasP is highly depen-
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dent on infected individuals adhering to treatment. It is widely agreed that
once antiretroviral treatment is started, it should not be interrupted. Incom-
plete viral suppression can cause the more sensitive strains of HIV to be
resistant, which are harder to treat [66]. Therefore, it is important to do re-
search on how individuals that drop out of ARV drugs affect the dynamics
of HIV/AIDS.
The study by Schilkowsky et al. [76], was aimed at identifying factors that
are associated with the health care of patients with HIV/AIDS who dropout.
This study was developed in a specialized health care unit of a University
hospital in Rio de Janeiro, Brazil, considering a stratified sample of adult
patients including all dropout cases (155) and 44.0% of 790 cases under reg-
ular follow-up. They used Bivariate analysis to identify associations that
are between health care dropout, demographic, socioeconomic and clinical
variables. Logistic and Cox regression models were also used to identify the
independent effects of the explanatory variables on risk for dropping out,
in the latter by incorporating information on the outcome over time.
Ballot et al. [44], examined attrition from HIV treatment programs as a re-
sult of the relationship between patient volume, human resource levels, and
patient characteristics. They used Cox proportional hazards models (regres-
sion model) to assess the association of patient volume, clinical staff burden,
and pharmacy staff burden with attrition while adjusting for patient char-
acteristics. After adjusting for patient characteristics, their results show that
patients attending clinics with medium pharmacy staff burden and high
pharmacy staff burden tend to have a higher risk of attrition. Likewise,
patients that are attending clinics with higher clinical staff burden have a
lower risk of attrition. Also, patients attending clinics with medium patient
volume levels and high patient volume levels had a higher risk of attrition.
They concluded that patients attending clinics with higher pharmacy staff
burden had a higher risk of attrition. These results highlight a potential area
within the health system where interventions could be applied to improve
the retention of these patient population.
Chikomo in [19] modelled retention and attrition of HIV positive patients
on ARV drugs for Warren Park Poly Clinic, Harare Province in the presence
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of a test and treat strategy. An HIV mathematical model with a treatment
option in the form of antiretroviral therapy for those infected with HIV was
proposed. The population is divided into three compartments namely: S(t)
which represents the population that is susceptible or at risk of contract-
ing the HIV virus at any time t, I(t) represents those infected with the HIV
virus and T(t) represents those who accept to take treatment in the form of
antiretroviral therapy. Infected individuals who, when initiated into treat-
ment continue to take treatment as being retained in care. Therefore, T(t)
compartment can also be called the retention compartment. Also, individ-
uals that drop out of treatment move back to the infected compartment.
Therefore dropout is considered as a parameter in the proposed model. The
model was fitted to data. According to the findings over the period from
2003− 2017, a total of 3236 infected individuals had been initiated for ART,
2519 of these were still retained in care and were regularly attending clinic
visits and finally, 716 had dropped out of the care system. The model dia-
gram is shown below;
Figure 2.2: The model extended in this thesis.
In this research work, the model developed will focus on the potential im-
pact of health care systems and dropouts on the dynamics of HIV/AIDS.
The driving force for the drop out is driven by the side effects of the ARV
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drugs. This work is innovative in proposing a function that describes how
the level of side effects impacts the dropping rate for the infected on treat-




Modelling the impact of different
health care systems and dropouts
on the dynamics of HIV/AIDS
3.1 Introduction
The world as a whole is faced with a diverse number of health problems in
which the human immunodeficiency syndrome (HIV/AIDS) is one of the
leading global health problems [6, 83]. The rate at which HIV infection has
been spreading and the mortality due to the disease over the years have
led to immense medical and scientific research [81]. According to the global
HIV statistics, 76.1 million [65.2− 88.0 million] people have become infected
with HIV and 35.0 million [28.9− 41.5 million] people have died from AIDS-
related illnesses since the start of the epidemic. As of 2016, 36.7 million
[30.8− 42.9 million] people were living with HIV, 1.8 million [1.6− 42.1 mil-
lion] people became newly infected with HIV and 1 million [830 000− 1.2
million] people died from AIDS-related illnesses [84]. Due to the mortal-
ity caused by HIV/AIDS, a significant amount of research has been done
and still ongoing so as to provide effective prevention techniques and find
a possible cure. However, to date, no HIV cure is available which implies
that the only fight against the disease remains its management [3]. National
Institute of Allergy and Infectious Diseases (NIAID) has helped in foster-
ing and promoting the development of highly active antiretroviral therapy
(HAART) that has led HIV infection from being fatal to a chronic condition
22
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that can be managed [20, 59]. As a result of this, an HIV infected person can
live a near-normal lifespan if they start the antiretroviral treatment early re-
gardless of the CD4 count [42, 79]. The use of antiretroviral treatment will
slow down the progression of HIV to AIDS [23, 32, 71]. Globally, 20.9 mil-
lion people are on antiretroviral therapy as of 2017 and AIDS-related deaths
have fallen by 48% since it had its pick in 2005 [84]. Likewise, infected indi-
viduals can go for antiretroviral treatment in either the private health care
system or the public health care system due to affordability.
Despite the fact that there are advances in the treatment of HIV/AIDS,
it is still very difficult to guarantee that patients that are diagnosed with
HIV/AIDS will continue with the necessary treatment. This is not only for
the patient to use ARV drugs appropriately and effectively but also for them
to always be available for outpatient health care services [76]. Various fac-
tors can lead to patients dropping out of ARV treatment programs. The
primary causes of patient dropouts are the drug side effects, poor adher-
ence, and poor health care services [25].
The importance of staying on ARV treatment has been highlighted by many
researchers, see for instance [25, 41]. Despite the advocacy and media cam-
paigns on the need to stay on treatment once one has started, a number
of dropouts are still being seen especially in resource-constrained commu-
nities. Mathematical models to investigate HIV treatment and associated
challenges have been presented. Schilkowsky et al. [76] investigated fac-
tors associated with HIV/AIDS treatment dropouts considering the CD4
count. Su et al. [78] also considered dropout as a result of the loss of treat-
ment follow-up from the health care system. Chikomo [19] also considered
dropout as a result of death and loss of follow-up from the health care sys-
tem for Warren Park Poly Clinic in Harare, Zimbabwe.
We consider the side effects of the ARV drugs as the driving force behind
dropouts. Side effects of ARV drugs can arise as a result of taking drugs
for a longer period of time, other medications interacting with HIV drugs
and non-adherence to ARV treatment plans. Some of the common side ef-
fects of ARV drugs are as follows; loss of appetite, Lipodystrophy (this is a
condition that makes people lose or gain fat in a certain area of the body), di-
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arrhoea, fatigue, allergic reactions, nausea and vomiting, trouble sleeping,
etc [16, 53]. Therefore, we assume that dropouts from private and public
health care systems respectively are influenced by the side effects of the an-
tiretroviral drugs. The most important aspect of side effects is the dosage or
amount of exposure to the drugs.
3.2 Model formulation
The human population, N(t), is partitioned into seven classes or compart-
ments. The susceptibles, S(t), which are those that are at risk of getting in-
fected at any time t; the infectives, I(t), that is those that have been infected
with the HIV virus; T1(t), those that are on antiretroviral therapy and in a
private health care system; T2(t), those that are on antiretroviral therapy but
in the public health care system; D1(t), those that dropout from antiretrovi-
ral therapy in the private health care system; D2(t), those that dropout from
antiretroviral therapy in the public health care system; and A(t), those with
full-blown AIDS, whom we assume, once they are in that class the health
care system to which they came from is immaterial.
Thus, at any time t ≥ 0, the total population is given by
N(t) = S(t) + I(t) + T1(t) + T2(t) + D1(t) + D2(t) + A(t). (3.1)
Susceptible individuals S(t) are recruited at a rate π, through births and
immigration. We do not consider the direct recruitment of infected individ-
uals. Individuals in all classes die naturally at a rate µ. Susceptible individ-
uals acquire HIV infection at a rate λ, referred to as the force of infection, so
that
λ =
β(I(t) + η1T1(t) + η2T2(t) + η3D1(t) + η4D2(t) + η5A(t))
N
, (3.2)
where ηi, i = 1, 2, 3, 4, 5, are modification parameters due to infectiousness
of all the other classes relative to I. The parameter β is the effective contact
rate i.e the contact that results in infection per unit time. We shall assume
that η1, η2 ∈ (0, 1] due to the effect of treatment in reducing the spread of
HIV while η3, η4, η5 > 1 due to increased viral loads as a result of dropping
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out from treatment programs and development of AIDS. The rate at which
infected individuals are absorbed into treatment is γ with a proportion ρ
moving into private health care and the remainder move into public health
care. Those that are not screened for the disease will eventually progress to
the AIDS class at a rate α1. Individuals in both treatment classes can drop
out of treatment as a result of the side effects of ARV drugs.
Functional responses have been used to model human behaviour, see for
instance [33, 60]. An example is a functional relationship proposed by Nja-
garah [60], which was used to model person-to-person contact in cholera
transmission dynamics. The author proposed a contact rate function that
is dependent on the proportion of the population that practices proper hy-





where the constant A is the scale parameter, η the shape parameter, βmaxh
is the rate of spread of the pathogen through person-to-person contact and
H is the level of hygiene. From equation 3.3, the effective contact rate will
reduce with increased level of hygiene, H.
Therefore, in this thesis, we propose a functional relationship f (ξ) which is
driven by the side effects to ARV drugs. It is plausible to believe that the
dropout rate will increase with increased levels of side effects. We assume
that individuals that drop out, return to treatment in their respective cate-
gories in relation to the health care system they can afford. We also assume
that individuals do not change health care systems. We argue that individ-
uals access the type of health care, especially HIV treatment, depending on
their level of affordability. In this model, we propose a dropout function
that is dependent on the side effects of antiretroviral drugs. We suggest a
sigmoidal function of the form (3.4). The function has a similar curve to that







where q is the shape parameter, k is the half saturated constant, ω0 is the
minimum dropout rate, ωmax is the maximum dropout rate, ξi, i = 1, 2
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denotes the side effects level of the antiretroviral drugs. We assume that
f (ξ1) < f (ξ2) given there are likely to be more dropouts from the public
health care system.
A typical example of a curve that depicts the change in the dropout rate is
shown in Figure 3.1.












































Figure 3.1: Dropout rate as a function of side effects level for people on
antiretroviral drugs.
The drop out rates is model by function (3.4). We allow the dropouts to
re-enter treatment programs at rates θ1 and θ2 for the private and public
health care systems respectively although at different rates. Individuals un-
der treatment in the private and public health care systems eventually de-
velop AIDS at rates α2 and α3 respectively. Those who drop out will also
develop AIDS at rates α4 and α5 for the private and public health care sys-
tems respectively. We assume a disease-related mortality rate, δ for those in
the AIDS class. The model description presented is reinforced by the model
diagram in Figure 3.2.
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Figure 3.2: The flow diagram showing the HIV/AIDS dynamics
The assumptions, model description and Figure 3.2 give rise to the follow-
ing set of nonlinear ordinary differential equations
dS
dt
= π − (λ + µ)S,
dI
dt
= λS− (µ + α1 + γ)I,
dT1
dt
= γρI − (µ + α2 + f (ξ1))T1 + θ1D1,
dT2
dt
= γ(1− ρ)I − (µ + α3 + f (ξ2))T2 + θ2D2,
dD1
dt
= f (ξ1)T1 − (µ + θ1 + α4)D1,
dD2
dt
= f (ξ2)T2 − (µ + θ2 + α5)D2,
dA
dt
= α1 I + α2T1 + α3T2 + α4D1 + α5D2 − (µ + δ)A.

(3.5)
with initial conditions S(0) = S0 > 0, I(0) = I0 ≥ 0, T1(0) = T1(0) ≥ 0,
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T2(0) = T2(0) ≥ 0, D1(0) = D1(0) ≥ 0, D2(0) = D2(0) ≥ 0, A(0) = A0 > 0,
where we assume that all the model parameters are positive.
3.3 Model properties and analysis
3.3.1 Positivity of solutions
We want to consider the positivity of the model system (3.5). We want to
prove that all the state variables remain non-negative and the solutions of
the model (3.5) with positive initial conditions will remain positive for all
t ∈ [0, ∞). This is definitely a condition to check since the model monitors
the human population. And the system of equations in (3.5) monitors the
flow between seven sub-population. Hence all parameters are assumed to
be non-negative.
Theorem 3.3.1. Given the initial conditions of the model system (3.5) are S(0) >
0, I(0) > 0, T1(0) > 0, T2(0) > 0, D1(0) > 0, D2(0) > 0, A(0) > 0. The
resulting solutions are all non-negative for all t ∈ [0, ∞).
Proof. It follows from the first equation of the model system (3.5) that
dS
dt




≥ −(λ + µ)S. (3.6)
Integrating both sides of equation (3.6) gives






Hence S(t) is always positive for S(0) > 0.
Similarly, from the second equation of the model system (3.5), we obtain
dI
dt
= λS− (α1 + µ + γ)I ≥ −(α1 + µ + γ)I,
whose solution is given by
I(t) ≥ I(0)e−(α1+µ+γ) > 0.
Similarly, it can be shown that the state variables T1(0) > 0, T2(0) > 0,
D1(0) > 0, D2(0) > 0, A(0) > 0, for all t > 0 respectively. Hence the
proof.
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3.3.2 Invariant region
Theorem 3.3.2. The set Ω =
{
(S, I, T1, T2, D1, D2, A) ∈ R7+|0 ≤ N ≤ πµ
}
is
positively invariant as a globally attractive set of model system (3.5).
Proof. The rate of change of the total population given by
dN
dt
= π − µN − δA ≤ π − µN. (3.7)
Solving equation (3.7) gives
N(t) ≤ e











It is important to note that if N(0) <
π
µ
then N(t) ≤ π
µ
. Therefore, every
solution with initial condition in R7+ remains in that region. This implies
that the set Ω is a positively invariant set for model system (3.5). On the








. So the set Ω is a globally
attractive set for the model system (3.5). Thus the model is well posed and
it can be said that it is epidemiologically meaningful.
3.3.3 Steady states analysis
In this section, we consider two steady states for the model system (3.5),
the disease-free equilibrium is the point in which there is no more disease
that is present in the population and the endemic equilibrium is the state in
which disease persist in the population.
We obtain the steady (equilibrium) points by setting the right-hand sides of
the system of equations (3.5) to zero so that
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π − (λ + µ)S∗ = 0 (3.9)
λS∗ − (α1 + µ + γ)I∗ = 0 (3.10)
γρI∗ − (µ + α2 + f (ξ1))T∗1 + θ1D∗1 = 0 (3.11)
γ(1− ρ)I∗ − (µ + α3 + f (ξ2))T∗2 + θ2D∗2 = 0 (3.12)
f (ξ1)T∗1 − (θ1 + µ + α4)D∗1 = 0 (3.13)
f (ξ2)T∗2 − (θ2 + µ + α5)D∗2 = 0 (3.14)






2 − (µ + δ)A∗ = 0. (3.15)
From equation (3.13) we have
D∗1 =
f (ξ1)T∗1
(µ + θ1 + α4)




(µ + θ1 + α4)
.
1
(µ + θ1 + α4)
is the average time an infected individual stays in drop out




(µ + θ2 + α5)




(µ + θ2 + α5)
.
1
(µ + θ2 + α5)
is the average time an infected individual stays in the drop
out class, D2, from the public health care system.
Substituting equation (3.16) into (3.11) we have
T∗1 =
γρI∗
(µ + α2 + f (ξ1)− θ1ψ1)
= ψ3 I∗, (3.18)
1
(µ + α2 + f (ξ1))
is the average time an infected individual stays in com-
partment T1,
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(µ + α2 + f (ξ1)− θ1ψ1)
=
γρ
(µ + α2 + f (ξ1))−
θ1 f (ξ1)
µ + θ1 + α4
=
γρ





µ + θ1 + α4
)(
f (ξ1)




(µ + α2 + f (ξ1))(1− x1x2)
=
γρ





(µ + θ1 + α4)
, x2 =
f (ξ1)
(µ + α2 + f (ξ1))
φ1 = x1x2.
We note that x1 is the proportion of individuals that drop out from the pri-
vate health care system class D1 that move back to treatment in the private
health care system T1 and x2 is the proportion of individuals in the private
health care system T1 that drop out from treatment.
Therefore,
φ1 is the proportion of individuals that drop out of D1 and are reintegrated
into treatment in the private health care system, T1.
Substituting equation (3.17) into (3.12) we have
T∗2 =
γ(1− ρ)I∗
(µ + α3 + f (ξ2)− θ2ψ2)
= ψ4 I∗, (3.19)
1
(µ + α3 + f (ξ2))
is the average time an infected individual stays in private
health care system class T1
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(µ + α3 + f (ξ2)− θ2ψ2)
=
γ(1− ρ)
(µ + α3 + f (ξ2))−
θ2 f (ξ2)
µ + θ2 + α5
=
γ(1− ρ)





µ + θ2 + α5
)(
f (ξ2)




(µ + α3 + f (ξ2))(1− x3x4)
=
γ(1− ρ)





µ + θ2 + α5
, x4 =
f (ξ2)
µ + α3 + f (ξ2)
φ2 = x3x4.
The epidemiological interpretation of the expression is such that;
x3 is the proportion of individual that drop out from public health care sys-
tem compartment D2, and move back to the treatment class T2,
x4 is the proportion of individuals in the public health care system class T2,
that drop out of treatment.
Therefore
φ2 is the proportion of individuals that drop out from compartment D2 and
are reintegrated into the treatment class T2.
Substituting equation (3.18) into (3.16) we have
D∗1 = ψ1ψ3 I
∗ = ψ5 I∗, (3.20)
where
ψ5 = ψ1ψ3 =
f (ξ1)
(µ + θ1 + α4)
× γρ
(µ + α2 + f (ξ1))(1− φ1)
=
f (ξ1)
(µ + α2 + f (ξ1))
× γρ
(µ + θ1 + α4)(1− φ1)
=
x2γρ
(µ + θ1 + α4)(1− φ1)
.
Substituting equation (3.19) into (3.17) we have
D∗2 = ψ2ψ4 I
∗ = ψ6 I∗, (3.21)
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where
ψ6 = ψ2ψ4 =
f (ξ2)
(µ + θ2 + α5)
× γ(1− ρ)
(µ + α3 + f (ξ2))(1− φ2)
=
f (ξ2)
(µ + α3 + f (ξ2))
× γ(1− ρ)
(µ + θ2 + α5)(1− φ2)
=
x4γ(1− ρ)
(µ + θ2 + α5)(1− φ2)
.
Substituting equations (3.18), (3.19), (3.20) and (3.21) into (3.15) we have
A∗ =
(α1 + α2ψ3 + α3ψ4 + α4ψ5 + α5ψ6)I∗
(µ + δ)
= ψ7 I∗, (3.22)
where
ψ7 =

















































(µ + α2 + f (ξ1))
, x6 =
α3
(µ + α3 + f (ξ2))
, x7 =
α4




(µ + θ2 + α5)
.
The epidemiological interpretations of some of the terms are as follows; x5
is the proportion of individual in compartment T1 that move to the AIDS
compartment A.
x6 is the proportion of individual in compartment T2 that move to AIDS
compartment A.
x7 is the proportion of individual in compartment D1 that move to AIDS
compartment A and x8 is the proportion of individual in compartment D2
that move to AIDS compartment A.
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 3. MODELLING THE IMPACT OF DIFFERENT HEALTH CARE
SYSTEMS AND DROPOUTS ON THE DYNAMICS OF HIV/AIDS 34
Substituting equations (3.18), (3.19), (3.20), (3.21) and (3.22) into (3.2) we
have
λ =







ψ8 = β(1 + η1ψ3 + η2ψ4 + η3ψ5 + η4ψ6 + η5ψ7).
Substituting equation (3.23) into (3.10) we have
ψ8 I∗S∗
N
− (µ + γ + α1)I∗ = 0[
ψ8S∗
N





















(µ + γ + α1)
+
βη1γρ
(µ + α2 + f (ξ1))(1− φ1)(µ + γ + α1)
+
βη2γ(1− ρ)
(µ + α3 + f (ξ2))(1− φ2)(µ + γ + α1)
+
βη3x2γρ
(µ + θ1 + α4)(1− φ1)(µ + γ + α1)
+
βη4x4γ(1− ρ)






(µ + γ + α1)
+
βx5γρ
(1− φ1)(µ + γ + α1)
+
βx6γ(1− ρ)
(1− φ2)(µ + γ + α1)
+
βx2x7γρ
(1− φ1)(µ + γ + α1)
+
βx4x8γ(1− ρ)
(1− φ2)(µ + γ + α1)
]}
= RI + RT1 + RT2 + RD1 + RD2 + RA. (3.25)
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(µ + γ + α1)
, RT1 =
βη1γρ
(µ + α2 + f (ξ1))(1− φ1)(µ + γ + α1)
RT2 =
βη2γ(1− ρ)














(µ + γ + α1)
+
βx5γρη5
(1− φ1)(µ + γ + α1)
+
βx6γ(1− ρ)η5
(1− φ2)(µ + γ + α1)
+
βx2x7γρη5
(1− φ1)(µ + γ + α1)
+
βx4x8γ(1− ρ)η5
(1− φ2)(µ + γ + α1)
]
1
(µ + γ + α1)




is the average time an infected individual stays in the full blown
AIDS class A.




A back substitution of I∗ = 0 into equations (3.18), (3.19), (3.20), (3.21) and
(3.22) results in the disease free equilibrium
E∗0 = (S











, 0, 0, 0, 0, 0, 0
)
.
Substituting equations (3.18), (3.19), (3.20) and (3.21) into (3.1) we have
N = S∗ + (1 + ψ3 + ψ4 + ψ5 + ψ6)I∗ = S∗ + ψ9 I∗, (3.26)
where
ψ9 = (1 + ψ3 + ψ4 + ψ5 + ψ6).
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Substituting equation (3.26) into (3.24) we have
S∗








Substituting equations (3.23), (3.26) and (3.27) into (3.9) we obtain
S∗ =
πR0ψ9




(R0 − 1)ψ8 + µR0ψ9
(3.29)




















(R0 − 1)ψ8 + µR0ψ9
(3.34)







∗) give the endemic equilibrium E1.
Note that if R0 = 1, the endemic equilibrium collapses to the disease-free
equilibrium. We thus have the following theorem on the existence of the
endemic equilibrium.
Theorem 3.3.3. If R0 ≤ 1, model (3.5) always has a disease free equilibrium E0.
However, if R0 > 1 the model has a unique endemic equilibrium E1.
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3.3.4 The reproductive number
The reproductive number R0 generated in equation (3.25) can be defined as
the average number of secondary infections caused by an infectious indi-
vidual during the period of infection [21]. In epidemiology modelling, the
reproductive number, R0, is used to find the conditions necessary to erad-
icate a disease [55]. It can be derived by using the next-generation matrix
method proposed by [21] and [86]. This involves finding the largest spectral
radius of the next generation matrix. A conclusion is then made based on
the value of R0. This means that when R0 < 1, each infected individual
produces on average, less than one new infected individual during his or
infectious period and hence the disease dies out. If R0 > 1, each infected







where, F is the new infection term and V other transfer terms.
F =

β βη1 βη2 βη3 βη4 βη5
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0





Q1 0 0 0 0 0
−γρ Q2 0 −θ1 0 0
−γ(1− ρ) 0 Q3 0 −θ2 0
0 − f (ξ1) 0 Q4 0 0
0 0 − f (ξ2) 0 Q5 0
−α1 −α2 −α3 −α4 −α5 Q6

where
Q1 = µ + α1 + γ Q2 = µ + α2 + f (ξ1) Q3 = µ + α3 + f (ξ2)
Q4 = µ + θ1 + α4Q5 = µ + θ2 + α5 Q6 = µ + δ. (3.35)
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The spectral radius of the next generation matrix FV−1 i.e the largest eigen-
value of FV−1. is the model basic reproductive number, which is denoted
by R0 is given by
ρ(FV−1) = R0 = RI + RT1 + RT2 + RD1 + RD2 + RA.
The reproductive number, and precisely the effective reproductive number,
in equation (3.25) has the following epidemiological interpretations:
• RI is the contribution of the infected individuals in I to the reproduc-
tion number.
• RT1 is the contribution of the infected individuals in T1 to the repro-
duction number.
• RT2 is the contribution of the infected individuals in T2 to the repro-
duction number.
• RD1 is the contribution of the infected individuals in RD1 to the repro-
duction number.
• RD2 is the contribution of the infected individuals in RD2 to the repro-
duction number.
• RA is the reproduction number as a result of the individuals with full-
blown AIDS in compartment A.
Theorem 3.3.4. The disease free equilibrium is locally asymptotically stable if
R0 < 1 and unstable if R0 > 1.
Proof. The proof follows the result in [86].
3.3.5 Global stability of the equilibria
In this section, we prove the global stability of the model equilibria E0 and
E1. To prove the global stability, Lyapunov functions, such as the ones used
in [64], will be used to prove the global stabilities of the disease-free and
endemic equilibrium.
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3.3.5.1 Global stability of disease-free equilibrium
Theorem 3.3.5. The disease-free equilibrium of the model system (3.5) is globally
asymptotically stable in Ω if R0 < 1 and unstable otherwise.
The proof of the theorem is given in Appendix A.1
3.3.5.2 Global stability of endemic equilibrium
To prove the global stability of the endemic equilibrium, we make an as-
sumption that the population does not change over the modelling time.
That is, π = µN + δA holds. This assumption is made for mathematical
tractability and may not be reflective of what would happen in reality espe-
cially in developing countries.
Theorem 3.3.6. The endemic equilibrium of the model system (3.5) is globally
asymptotically stable in Ω if π = µN + δA and R0 > 1.
The proof of the theorem is given in Appendix A.2
3.4 Numerical simulations
In this section, to illustrate the dynamic behaviour of model system (3.5),
simulations are carried out in Matlab by using the range of parameters in
Table 3.3 which are also used for the data fitting. We determine the pop-
ulation of dropouts from treatment when the reproduction number R0 is
greater than one and when it is less than one. A few of the parameters are
known. The unknown parameters are therefore estimated. Therefore, it is
important to carefully study the disease dynamics, putting into considera-
tion individual differences, location, social-economic status while selecting
parameter values. Our focus is on Zimbabwe given that the model will
be validated using data from Warren Park in Zimbabwe. The death rate
µ = 0.016 was calculated from the life expectancy in Zimbabwe which was
taken to be 61.16years [85]. However, according to statistics, the life ex-
pectancy of Zimbabwe has been varying, in 1992 it was 55.34years and later
dropped to 44.11 in 2002 [85]. We used the following initial conditions for
the classes in model system (3.5): S(0) = 87768, I(0) = 10, T1(0) = 6,
T2(0) = 5, D1(0) = 4, D2(0) = 6, A(0) = 0. The values of the initial
conditions were hypothetically chosen based on the HIV prevalence rates
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in Harare, Zimbabwe [72], considering the population of Warren Park in
Harare, Zimbabwe [24] and the data collected from Warren park polyclinic
in Zimbabwe.
3.4.1 Application to data from Warren Park in Zimbabwe
Southern Africa is the hardest hit by the epidemic. Zimbabwe has been
grossly affected by HIV, with the first reported HIV infection case in 1985
[28]. As of 2012, the Zimbabwe Demographic and Health Survey (ZDHS)
had a national estimate of HIV prevalence at 15% [5]. Even though HIV/AIDS
is a severe epidemic, prevalence has begun to show signs of decline in Zim-
babwe but the country is still ranked among the top 10 countries in the
world [4]. Warren Park polyclinic located in Harare, Zimbabwe, is one of
the clinics that treat HIV/AIDS patients in Harare. Information from the
Ministry of Health classifies Warren Park Poly Clinic as a Level 5 clinic-
(with the highest ranking when it comes to data quality). This implies that
they have entered into the Electronic Patient Monitoring System (EPMS) all
patients who were in the hospital booklets that had HIV/AIDS since 2000.
In this section, we fit the model system (3.5) to the data of individuals
that dropout from treatments which is obtained from Warren Park from
(2000− 2017). We only make use of the available data from one clinic. For
data fitting, parameters that give the best fit are estimated with the use of
the Least Square method in Matlab, where the unknown parameters are
estimated by assigning upper and lower bounds. The coefficient of deter-
mination R2 (which is used to determine how well the model fits the data)
is 0.773, this implies that the model fit the data with 77.3%.
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Figure 3.3: The total number of enrollment into ART treatment from 2000−
2017, retention and attrition at Warren Park Poly Clinic. A total of 3235
people had been initiated for ART, 2519 of these (77.867%) were still retained
in care and were regularly attending clinic visits and 716 of these (22.132%)
were found to have dropped out of the care system.
Table 3.1: Retention and attrition by disaggregation using age
Age group Retention AttritionMale Female Total Male Female Total
< 1
1− 9 9 11 20 4 2 6
10− 14 14 12 26 3 6 9
15− 19 7 22 29 6 6 12
20− 24 16 93 109 10 28 38
25− 49 550 1268 1818 165 371 536
≥ 50 225 292 517 51 64 115
From Table (3.1), it can be seen that there are no children that are under the
age of 1 enrolled in treatment in the clinic. This shows that there has been
a great effort in the prevention of mother to child transmission. Likewise,
attrition was found to be higher among the age group 25− 49.
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 3. MODELLING THE IMPACT OF DIFFERENT HEALTH CARE
SYSTEMS AND DROPOUTS ON THE DYNAMICS OF HIV/AIDS 42
Table 3.2: Data set that shows the cumulative number of infected individu-
als that drop out of treatment in Warren Park, Zimbabwe from 2000-2017.



















From Figure 3.4, the results show that the total number of people who drop
out of treatments each year in Warren Park has been increasing. This also
shows that each year there is always a record of individuals that are on ARV
drugs but drop out of treatment in each year, a clear indication of the con-
sistent data recording. Therefore, strategies must be put in place to make
individuals that drop out of treatment return back to treatment.
Please note that the data use does not differentiate between private and pub-
lic health care systems. Therefore, in the model fitting, we added together
both the private and public health care systems.
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Figure 3.4: Model system (3.5) fitted to data for individuals that dropout
from treatment from (2000− 2017). The solid line indicates the model fit to
the data and the circles indicate the actual data.
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3.4.2 Time series plots
Table 3.3: Range of values used for the parameters and the estimated values
that give the best fit. Units are in year−1
Parameter Description Range Source
π Recruitment (2000 - 3000) Estimated
µ Natural mortality rate 0.016 [85]
γ
Rate at which I proceed
to T1 and T2
(0 - 0.6) Estimated
ρ Proportion of γ to T1 and T2 (0.1 - 0.73) Estimated
α1
Progression rate to AIDS
from infected individuals I (0.05 - 0.2) Estimated
α2 Progression rate to AIDS from T1 (0 - 0.5) Estimated
α3 Progression rate to AIDS from T2 (0.0998 - 0.4) Estimated
α4 Progression rate to AIDS from D1 (0.001 - 0.7) Estimated
α5 Progression rate to AIDS from T2 (0.001 - 0.090) Estimated
θ1 Rate at which D1 move back to T1 0.02 - 0.099 Estimated
θ2 Rate at which D2 move back to T2 (0.05 - 0.099) Estimated
f (ξ1)
Rate at which T1 move to D1
due to side effect of ART (0 - 0.06) Estimated
f (ξ2)
Rate at which T2 move to D2
due to side effect of ART (0 - 0.069) Estimated
β Effective transmission rate (0.1 - 0.8) Estimated
η1 Relative infectivity due to T1 class (0.1 - 0.5) Estimated
η2 Relative infectivity due to T2 class (0.15 - 0.7) Estimated
η3 Relative infectivity due to D1 class (1 - 1.05) Estimated
η4 Relative infectivity due to D2 class (1 - 1.08) Estimated
η5 Relative infectivity due to AIDS class (1 - 1.10) Estimated
δ Disease induced death rate (0.001 - 0. 07) Estimated
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Figure 3.5: The result of simulations of the dynamics of Model system (3.5)
for the estimated parameter values π = 2412, µ = 0.016, γ = 0.098, ρ =
0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, θ1 =
0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, f (ξ1) = 0.021, f (ξ2) = 0.034, η1 =
0.257, η2 = 0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.004, where R0 =
0.0469. The value of R0 < 1 describes a stable disease-free state.
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Figure 3.6: The result of simulations of the dynamics of Model system (3.5)
for the estimated parameter valuesπ = 2412, µ = 0.016, γ = 0.098, ρ =
0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, θ1 =
0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, f (ξ1) = 0.021, f (ξ2) = 0.034, η1 =
0.257, η2 = 0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313, where R0 =
5.1599. The value of R0 > 1 describes a an endemic state.
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In Figure 3.5, it can be observed that model system (3.5) approaches a stable
disease-free state when reproduction number R0 = 0.0469. The time series
plots for the infected and dropouts reduce to zero asymptotically. The same
trends are depicted for the treatments and AIDS compartments. This im-
plies that the disease-free equilibrium is globally stable when R0 < 1 and
unstable otherwise.
In Figure 3.6, it can also be observed that the model system (3.5) is at a stable
endemic state since the reproduction number R0 = 5.1599. The infected and
dropouts compartments increases due to the fact that the disease persists in
the population. It can also be seen that the private health care system class
of infectives not under treatment peaks at close to 18000 when compared to
close to 20000 of that of the public health care system.
Figure 3.7: R0 as a function of side effect level of people on ARV drugs in the
private health care system. The rest of the parameter values are: ωmax = 0.7,
ω0 = 0.1, k = 0.1, q = 0.6, π = 2412, µ = 0.016, γ = 0.098, ρ = 0.45, α1 =
0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, θ1 = 0.076, θ2 =
0.071, ρ = 0.45, δ = 0.043, f (ξ1) = 0.021, η1 = 0.257, η2 = 0.345, η3 =
1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
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Figure 3.8: R0 as a function of side effect level of people on ARV drugs in the
public health care system. The rest of the parameter values are: ωmax = 0.9,
ω0 = 0.2, k = 0.1, q = 0.6, π = 2412, µ = 0.016, γ = 0.098, ρ = 0.45, α1 =
0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, θ1 = 0.076, θ2 =
0.071, ρ = 0.45, δ = 0.043, f (ξ1) = 0.021, η1 = 0.257, η2 = 0.345, η3 =
1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
Figures 3.7 and 3.8 are obtained by replacing the estimated values of f (ξ1)
and f (ξ2) respectively with the functional response f (ξi) in the expression
in (3.4) for variables ξ1 and ξ2 in (3.25). In Figure 3.7 it is observed that there
is an inverse relationship between R0 and ξ1, this shows that as the side ef-
fect level of people on antiretroviral drugs increases, the reproductive num-
ber increases. Also, Figure 3.8 shows an inverse relationship between R0
and ξ2. Therefore, it is important to reduce the toxicity of ARV drugs so as
to reduce it’s side effects on infected individuals on antiretroviral treatment.
This will in turn help in fighting the AIDS epidemic.
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Figure 3.9: Potential number of dropouts over time, which is the population
that dropout from private health care systems with ωmax = 0.5 and ω0 =
0.01.
Figure 3.10: Potential number of dropouts over time, which is the popu-
lation that dropout from public health care systems with ωmax = 0.5 and
ω0 = 0.01.
In Figure 3.9, the impact of the dropout rate parameter f (ξ1) due to side ef-
fects of the antiretroviral drugs on the infected population under treatment
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in the private health care system was investigated. It was paramount to
know how side effects affect the dropouts in order to design interventions
on how to reduce them. The shaded area in 3.9 represents the potential
number of dropouts over time. We observed that as side effect increases,
the number of dropouts from treatment increases significantly. In such a
scenario, we are able to quantify the impact of side effects on the number
of dropouts. Also, the same holds for the public health care system in Fig-
ure 3.10 considering f (ξ2). The difference is that the potential number of
dropouts overtime is higher in the public health care system when com-
pared to the private health care system.
3.5 Sensitivity analysis
Sensitivity analysis is the study of how the changes in parameters or varia-
tion in parameter inputs in a model can lead to a response in the output [93].
We use sensitivity analysis to show which parameter has a great effect on
the reproduction number R0 either with a positive or negative correlation
[62]. Sensitivity analysis also enables us to know important parameters that
are capable of altering the value of the output or that can cause a change
in the structure of the model [68]. We use the Latin Hypercube Sampling
(LHS) method. The main reason for LHS/PRCC sensitivity analysis is be-
cause it is a type of sensitivity analysis that enables the use of all parameters
space of the model with just a minimum number of computer simulations
[14].
In this work, we estimated the effect of variation of parameters to the sen-
sitivity of the reproduction number R0 using Matlab. This enabled us to
determine the impact of each parameter in system (3.5) for a chosen out-
come variable.
The estimated range of parameters used for the simulations are found in Ta-
ble 3.3. Parameters with positive sensitivity indices imply that there will be
increase in the reproduction number R0 whenever they are increased (pos-
itive correlation) while parameters with negative sensitivity indices imply
the opposite.
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From Figure 3.11, it shows that positive correlation exists between R0 and
f (ξ1), also positive correlation exists between R0 and f (ξ2). It indicates that
side effects of antiretroviral drugs play an important role in increasing the
epidemic and hence adequate measures must be put in place to reduce the
side effects of the ARV drugs in order to reduce the rate of dropout from
treatment.
Also from Figure 3.11, it can be seen that negative correlation exist between
R0 and γ, θ1, θ2. This implies that treatment intervention that has been put
in place should be sustained and dropouts should be traced and encouraged
to move back to treatment programs for the control of the epidemics.
Table 3.4: Sensitivity indices of the parameters that is used to carryout the
simulation
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Figure 3.11: The Latin Hypercube Sampling-Partial Rank Correlation Coef-
ficients (LHS/PRCCs) for the range of parameters from. Note d1 and d2
represent f (ξ1) and f (ξ2) respectively. It can be seen from the plot that the
parameters that are positive have the high chance of making the epidemic
worse and the parameters that are negative have a high potential of reduc-
ing the epidemic.
3.5.1 Effects of varying β on the dynamics of HIV/AIDS
In order to investigate the effect of effective transmission rate β on the dy-
namics of HIV/AIDS, we run a simulation on Model system (3.5) by using
different values of β. The result is shown in Figure 3.12.
Stellenbosch University https://scholar.sun.ac.za
CHAPTER 3. MODELLING THE IMPACT OF DIFFERENT HEALTH CARE
SYSTEMS AND DROPOUTS ON THE DYNAMICS OF HIV/AIDS 54
Figure 3.12: The result of simulations of the dynamics of Model system (3.5)
for the estimated parameter values π = 2412, µ = 0.016, γ = 0.098, ρ =
0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, θ1 =
0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, f (ξ1) = 0.021, f (ξ2) = 0.034, η1 =
0.257, η2 = 0.345, η3 = 1.016, η4 = 1.03, η5 = 1.043. The result shows the
way the steady states transit from the disease-free state to endemic state as
β increases.
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From Figure 3.12, it can be seen that the dynamics of model system (3.5)
changes as the transmission rate (β) increases. This implies that β is an im-
portant parameter in the dynamics of HIV/AIDS. The populations of each
class change from the stable disease-free state to an endemic state. This is
definitely correct because from the interpretation of Figure 3.12 R0 increases
as β increases. Therefore, biologically it can be confirmed because when the
rate at which people get infected increases, then this, in turn, will increase
the reproduction number. Thus, if there is no intervention regarding the epi-
demics, then the disease will continue to increase in the population. There
are quite a number of reasons that could cause this, either as a result of
unavailability or low use of condoms, high sexual risk (multiple partners),
high rate of attrition from ARV and probable resistance to ARV drugs.
3.5.2 Effects of varying γ on the infected and treatment
classes
We investigated the population of the infected and treatment classes of Model
system (3.5) as treatment rate (γ) increases.
Figure 3.13: Effect of varying γ on R0.
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Figure 3.14: The result of simulations of the dynamics of Model sys-
tem (3.5) for the estimated parameter values π = 2412, µ = 0.016, ρ =
0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 = 0.052, f (ξ1) =
0.021, f (ξ2) = 0.034, θ1 = 0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, η1 =
0.257, η2 = 0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313. The re-
sult shows the dynamics of the infected and treatment populations as γ
increases.
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We note from Figure 3.13 that as γ increases the reproduction number de-
creases. This is an indication that a lot of efforts must be made so as to in-
crease compliance to treatment which is already in place and to enrol more
people living with HIV/AIDS into treatment and also to encourage indi-
viduals not to drop out from treatment in order to reduce the burden of the
disease.
Figure (3.14) shows the result of varying γ on the infected and treatment
population. It can be seen that as γ increases the infected population de-
creases and the treatment population increases. The biological implication
is that as more people that are infected are enrolled in treatment, the viral
load in the individuals reduces and the density of the infected population
reduces. This, in turn, will make the reproduction number to reduce as peo-
ple start receiving ART and there is adherence to the treatment. Therefore,
individuals must be encouraged to enrol in treatment for the burden of the
disease to reduce.
3.5.3 Effects of varying θ1, θ2, f (ξ1), f (ξ2) on the dynamics
of the dropout compartments
In order to determine the effects of θ1, θ2, f (ξ1), f (ξ2) on the dynamics of
the dropouts of the model system (3.5) we vary the parameters and observe
how the time series plot change as the parameters change. The results of the
simulations are shown in Figures 3.15, 3.16, 3.17 and 3.18.
Figure 3.15 shows that increasing f (ξ1) and f (ξ2) increases the number of
D1 and D2 with D2 > D1. This implies that when side effects to ARV drugs
increases, individuals that drop out of treatment increases which also, in
turn, makes the reproduction number R0 to increase. As a result, reduction
of side effects has the potential to impact retention of individuals under
treatment. Figure 3.15 quantifies the effects of side effects on the number of
dropouts.
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Figure 3.15: Variation of the model system (3.5) time series plots when f (ξ1)
and f (ξ2) are varied using the parameter values π = 2412, µ = 0.016, γ =
0.098, ρ = 0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 =
0.052, θ1 = 0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, η1 = 0.257, η2 =
0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
Figure 3.16 shows that increasing f (ξ1) and f (ξ2) decreases the number of
people in private health care system T1 and public health care system T2. It
is thus important for infected individuals to remain in treatment to main-
tain viral suppression which in turn reduces the spread of the epidemic.
Figure 3.17 shows that as θ1 and θ2 increases, the population of D1 and
D2 decreases respectively. This implies that when the rate at which peo-
ple move back into treatment after dropout increases, then the reproduc-
tion number R0 decreases. So it is important that individuals that dropout
from treatment be encouraged to move back to treatment so as to control
the disease escalation due to the potential of viral suppression controlling
the spread of the epidemic.
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Figure 3.16: Variation of the model system (3.5) time series plots when f (ξ1)
and f (ξ2) are varied using the parameter values π = 2412, µ = 0.016, γ =
0.098, ρ = 0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 =
0.052, θ1 = 0.076, θ2 = 0.071, ρ = 0.45, δ = 0.043, η1 = 0.257, η2 =
0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
Furthermore, Figure 3.18 shows that as θ1 and θ2 increases, the population
of T1 and T2 increases respectively. Biologically, this means that since indi-
viduals that move back will start taking ARV drugs back, then the repro-
duction number R0 decreases which will make the viral load reduce and
also affecting others will also be minimized.
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Figure 3.17: Variation of the model system (3.5) time series plots when θ1
and θ2 are varied using the parameter values π = 2412, µ = 0.016, γ =
0.098, ρ = 0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 =
0.052, f (ξ1) = 0.021, f (ξ2) = 0.034, ρ = 0.45, δ = 0.043, η1 = 0.257, η2 =
0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
Figure 3.18: Variation of the model system (3.5) time series plots when θ1
and θ2 are varied using the parameter values π = 2412, µ = 0.016, γ =
0.098, ρ = 0.45, α1 = 0.0412, α2 = 0.0214, α3 = 0.0312, α4 = 0.0521, α5 =
0.052, f (ξ1) = 0.021, f (ξ2) = 0.034, ρ = 0.45, δ = 0.043, η1 = 0.257, η2 =
0.345, η3 = 1.016, η4 = 1.03, η5 = 1.04, β = 0.313.
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Contour plot in Figures 3.19 and 3.20 are used to ascertain the relationship
between some selected pairs of parameters and R0. Figure 3.19 shows that
when both θ1 and θ2 (the rate at which individuals that drop out of treat-
ment return back to treatment) are increased, they decrease the reproduc-
tion number R0. Biologically, moving back to treatment after dropout has
a positive impact on the reproduction number R0. However, from Figure
3.20 when both f (ξ1) and f (ξ2) (side effects to ARV drug) are increased,
the reproduction number increases. Also, we can notice that the reproduc-
tion number R0 increases significantly as side effects increases. Therefore,
we can conclude that the rate at which individuals dropout from treatment
is a major concern for health policymakers. Thus, adequate public health
measures such as sensitizing individuals on ART and managing side effects
should be escalated in order to control people from dropping out of treat-
ment, so as to control HIV/AIDS.
Figure 3.19: Contour plot of R0 as a function of θ1 and θ2.
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Figure 3.20: Contour plot of R0 as a function of f (ξ1) and F(ξ2).
This study of the potential impact of health care systems and dropouts





In this thesis, we proposed a deterministic model for HIV/AIDS. We in-
cluded the treatment of individuals with respect to the type of health care
system (private or public) in which they are enrolled. Dropouts from treat-
ment are as a result of side effects to ARV drugs. We explicitly computed the
steady states: the disease-free and endemic equilibrium points of the model
system (3.5). The basic reproduction number R0 was obtained and used
for the analysis of the steady states. Apart from proving the existence of
the endemic state of model system (3.5), we also established theorems that
provide the global stabilities of the disease and endemic states. Lyapunov
functions are presented to prove the global stabilities of the disease-free and
endemic equilibrium points of the model system (3.5). The results show that
disease-free equilibrium point is globally asymptotically stable for R0 < 1
and endemic equilibrium is globally stable for R0 > 1. The global stabil-
ity result suggests that the model has a forward transcritical bifurcation as
shown in Figure 4.1.
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Figure 4.1: Forward transcritical bifurcation for R0.
The implications of global stability, is that, irrespective of the initial condi-
tions, every trajectory in the invariant region tends to the disease free equi-
librium point if R0 < 1. On the other hand, if R0 > 1, then all the trajectories
in the invariant region tend to the endemic equilibrium point. These results
have implications on the epidemic, and the elimination of the epidemic de-
pends on the value of R0.
Simulations were carried out to track the dynamics of the model system
(3.5) at both the disease and endemic equilibrium points. Time series plots
are given to show the dynamics of each compartment over time for the cases
R0 < 1 and R0 > 1.
The results obtained from the sensitivity analysis enabled us to determine
the parameters which have a significant impact on the dynamics of the dis-
ease. Sensitivity indices were obtained for various parameters. We note that
reducing parameters with positive signs of their sensitivity indices reduces
the reproduction number R0, hence a reduction in the growth of the epi-
demic. Therefore, interventions should target on reducing such parameters.
The sensitivity analysis and numerical results also show that the side effects
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of ARV drugs have a positive correlation with the reproduction number R0.
This implies that decreasing side effects of ARV drugs decreases R0. There-
fore when side effects to ARV drugs decrease, individuals that drop out
from treatment also decreases thus reducing the transmission of the disease.
This, in turn, also will reduce the rate at which individuals develop AIDS
and as a result help in the control of the disease. Thus, when the number of
individuals that return to treatment after dropout increases, this will in turn
help in reducing the reproduction number R0. This result is supported by
the known relationship between disease transmission by virally suppressed
individuals who are assumed to have a reduced chance of transmitting the
virus to the uninfected.
The model system (3.5) was fitted to data of individuals that drop out of
treatment in order to see the trends of individuals that drop out of treat-
ment as shown in Fig. 3.4. We emphasize here that while the model is
divided into two healthcare systems, the data that was used for the fitting
of the model was not divided according to the healthcare system. Since
Warren Park, is a middle income suburb, we assumed that the drop outs
from the two healthcare systems can be combined for the fitting process.
The model is fitted using the least squares method and is found to fit rela-
tively well to the available data. Since the data is not separated according
to the healthcare system, the modelling framework presented in this thesis
suggests that data from the private and public health care system should be
presented separately for the sole purpose of monitoring HIV/AIDS in both
systems. It is, however, important to note that most of the data collected are
donor-funded and as such, donors deal directly with the public health care
systems.
In conclusion, an increase in side effects of ARV drugs could bring about
an increase of individuals that dropout from treatment, which will have a
great impact on the dynamics of HIV/AIDS. The quantification of the side
effects is an important research exercise that warrants investigation.
Like any modelling adventure, this work has some limitations. First, the
majority of the parameters are estimated. We had to make use of the iter-
ative method using Matlab in order to get an estimated value for the pa-
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rameters as a result of the fact that there is no availability of published data
on the parameters. Second, we used data from just one clinic but data from
both private and public health care systems could give a better estimates for
our parameters. Third, the model we use does not put into consideration
vertical transmission and other forms of transmission, which have greatly
impacted the HIV/AIDS epidemic globally. Fourth, the model does not
consider other forms of interventions, such as PrEP, media campaigns, vol-
untary male circumcision. In addition, the drop out rate may not necessarily
be constant throughout the epidemic period. Last, Stochasticity that can be
attributed to the side effect level of people on ARV drugs could also have an
influence on the pattern of the infection. Therefore, considering a stochastic
approach could give a better picture of the dynamics of the dropout classes.
Despite these shortcomings, the model presents a foundation for further
investigations of different healthcare systems, especially in countries with
function private and public health care systems. This forms our future re-
search, as we extend the current work.
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Appendix A
Global stability of the equilibria
A.1 Proof of theorem 3.3.5
Proof. Let us consider the following Lyapunov function
V = I + ν1T1 + ν2T2 + ν3D1 + ν4D2 + ν5A, (A.1)
where νi, i = 1, · · · , 5 are positive constants that will be determined.
• V = 0 at the steady state, since I(t) = T1(t) = T2(t) = D1(t) =
D2(t) = A(t) = 0 at (Disease Free Equilibrium).
• V > 0 at any other point not equal to the steady state (DFE), since
I(t) > 0, T1(t) > 0, T2(t) > 0, D1(t) > 0, D2(t) > 0, A(t) > 0.
• V̇ < 0, then the steady state is globally stable.
Differentiating equation (A.1) with respect to t, we have
V̇ = İ + ν1Ṫ1 + ν2Ṫ2 + ν3Ḋ1 + ν4Ḋ2 + ν5Ȧ. (A.2)
Substituting (3.5) into (A.2), we have
V̇ = λS−Q1 I + ν1[γρI −Q2T − 1 + θ1D− 1] + ν2[γ(1− ρ)I −Q3T2+
θ2D2] + ν3[ f (ξ1)T1 −Q4D− 1] + ν4[ f (ξ2)T2 −Q5D2] + ν5[α1 I + α2T1+
α3T2 + α4D1 + α5D2 −Q6A], (A.3)
where the values of Qi, i = 1, · · · , 6 are expressed in equation (3.35).
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From equation (3.8), we know that
N
S
≤ 1. Substituting it into equation
(A.4) gives
V̇ ≤ [β−Q1 + ν1γρ + ν2(γ(1− ρ)) + ν5α1] I + [η1β− ν1Q2 + ν3 f (ξ1)+
ν5α2]T1 + [η2β− ν2Q3 + ν4 f (ξ2) + ν5α3] T2 + [η3β + ν1θ1 − ν3Q4 + ν5α4] D1
















I + [η1β− ν1Q2 + ν3 f (ξ1)
+ ν5α2]T1 + [η2β− ν2Q3 + ν4 f (ξ2) + ν5α3] T2 + [η3β + ν1θ1 − ν3Q4 + ν5α4]
D1 + [η4β + ν2θ2 − ν4Q5 + ν5α5] D2 + [η5β− ν5Q6] A (A.5)
Solving for νi, i = 1, · · · , 5 so that the coefficient of T1, T2, D1, D2, A are zero,
we have
ν1 =
β[Q4(Q6η1 + α2η5) + f (ξ1)(Q6η3 + α4η5)]
Q6[Q2Q4 − f (ξ1)θ1]
(A.6)
ν2 =
β[Q5(Q6η2 + α3η5) + f (ξ2)(Q6η4 + α5η5)]
Q6[Q3Q5 − f (ξ2)θ2]
(A.7)
ν3 =
β[Q2(Q6η3 + α4η5) + θ1(Q6η1 + α2η5)]
Q6[Q2Q4 − f (ξ1)θ1]
(A.8)
ν4 =
β[Q3(Q6η4 + α5η5) + θ2(Q6η2 + α3η5)]
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βγρ[Q4(Q6η1 + α2η5) + f (ξ1)(Q6η3 + α4η5)]
Q1Q6[Q2Q4 − f (ξ1)θ1]
+
βγ(1− ρ)[Q5(Q6η2 + α3η5) + f (x2(Q6η4 + α5η5))]













Q1(Q2Q4 − f (ξ1)θ1)
+
βγρα2η5Q4
Q1Q6(Q2Q4 − f (ξ1)θ1)
+
βγρη3 f (ξ1)
Q1(Q2Q4 − f (ξ1)θ1)
+
βγρα4η5 f (ξ1)
Q1Q6(Q2Q4 − f (ξ1)θ1)
+
βγ(1− ρ)η2Q5
Q1(Q3Q5 − f (ξ2)θ2)
+
βγ(1− ρ)α3η5Q5
Q1Q6(Q3Q5 − f (ξ2)θ2)
+
βγ(1− ρ)η4 f (ξ2)
Q1(Q3Q5 − f (ξ2)θ2)
+
βγ(1− ρ)α5η5 f (ξ2)





 βQ1 + βγρη1Q1Q2(1− f (ξ1)θ1Q2Q4













































































≤ Q1[(RI + RT1 + RT2 + RD1 + RD2 + RA)− 1]I
≤ Q1(R0 − 1)I. (A.11)
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= 0 is (0, 0, 0, 0, 0, 0). By Lasalle’s invariant principle
from [45] we conclude that model (3.5) is globally asymptotically stable at
E0. Epidemiologically this means that the disease dies out eventually re-
gardless of the initial states of the system.
A.2 Proof of theorem 3.3.6
Proof. Lets consider equation (3.9) - (3.15) at steady states, so that
π = λS∗ + µS∗, (A.12)










































Lets consider the following Lyapunov function
V = (S− S∗ ln S) + τ1(I − I∗ ln I) + τ2(T1 − T∗1 ln T1) + τ3(T2 − T∗2 ln T2)
+ τ4(D1 − D∗1 ln D1)τ5(D2 − D∗2 ln D2) + τ6(A− A∗ ln A), (A.19)
where, τi, i = 1, · · · , 6 are constants that will be determined.
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Substituting the expressions for Ṡ, İ, Ṫ1, Ṫ2, Ḋ1, Ḋ2, Ȧ from the model system
















































(α1 I + α2T1 + α3T2 + α4D1 + α5D2 − (µ + δ)A). (A.21)































































































Calculating terms relating to state variable S from equation (A.22) and sub-



































































































































































































Calculating terms relating to state variable I from equation (A.22) and
















































































































































Substitute equation (A.25) into (A.28) and simplify, yields
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Substitute equation (A.25) into (A.34) and simplify, we have


































Substitute equation (A.25) into (A.36) and simplify, we have
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Combining the expressions in equations (A.26), (A.29), (A.31), (A.33), (A.35),






+ f (r, u, v, w, x, y, z),
where
f (r, u, v, w, x, y, z) = β0 I∗S∗ + β0η1T∗1 S
∗ + β0η2T∗2 S
∗ + β0η3D∗1 S
∗ + β0η4D∗2
S∗ + β0η5A∗S∗ + τ1β0 I∗S∗ + τ1β0η1T∗1 S
∗ + τ1β0η2T∗2 S
∗+
τ1β0η3D∗1 S
∗ + τ1β0η4D∗2 S
∗ + τ1β0η5A∗S∗ + τ2γρI∗+
τ2θ1D∗1 + τ3γ(1− ρ)I∗ + τ3θ2D∗2 + τ4 f (ξ1)T∗1 + τ5 f (ξ2)T∗2







I∗S∗ − β0 I∗S∗) + rv(τ1β0η1T∗1 S∗ − β0η1T∗1 S∗) + rw(τ1β0η2
T∗2 S
∗ − β0η2T∗2 S∗) + rx(τ1β0η3D∗1 S∗ − β0η3D∗1 S∗) + ry(τ1
β0η4D∗2 S








+ u(β0 I∗S∗ − τ1β0 I∗S∗ − τ1β0η1T∗1 S∗−
τ1β0η2T∗2 S
∗ − τ1β0η3D∗1 S∗ − τ1β0η4D∗2 S∗ − τ1β0η5A∗S∗
+ τ2γρI∗ + τ3γ(1− ρ)I∗ + τ6α1 I∗) + v(β0η1T∗1 S∗ − τ2
γρI∗ − τ2θ1D∗1 + τ4 f (ξ1)T∗1 + τ6α2T∗1 ) + w(β0η2T∗2 S∗−
τ3γ(1− ρ)I∗ − τ3θ2D∗2 + τ5 f (ξ2)T∗2 + τ6α3T∗2 ) + x(β0η3
D∗1 S
∗ + τ2θ1D∗1 − τ4 f (ξ1)T∗1 + τ6α4D∗1) + y(β0η4D∗2 S∗+





∗S∗ − τ6α1 I∗−























































(−τ4 f (ξ1)T∗1 ) +
w
y































Solving for τi, i = 1, · · · , 6 by using equation (A.40), all the coefficients of


















































γ(1− ρ)I∗ f (ξ2)T∗2 P
+
β0η5γ(1− ρ)D∗2 I∗A∗S∗

























P = I∗α1 + T∗1 α2 + T
∗
2 α3 + D
∗
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Substituting τi, i = 1, · · · , 6 into equation (A.40), simplifying and collecting
like terms, we have
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+ f (r, u, v, w, x, y, z) ≤ 0.
Also V̇ = 0 only if r = 1, u = v = w = x = y = z. Thus, the func-
tion V satisfies the Lyapunov stability theorem. This implies that the set{
(S, I, T1, T2, D1, D2, A) ∈ Ω|V̇(S, I, T1, T2, D1, D2, A) = 0
}
consist only the
point E1 (Endemic equilibrium). Therefore, by Lyapunov’s direct method,
E1 is globally asymptotically stable in the region Ω. By Lasalle’s invariant
principle from [45] we conclude that model (3.5) is globally asymptotically
stable at E1. Epidemiologically this means that the disease persist regardless
of the initial states of the system.
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